Construction of the Six-IncRNA Prognosis Signature as a Novel Biomarker in Esophageal Squamous Cell Carcinoma

Ze-Jun Zheng¹, Yan-Shang Li¹,², Jun-De Zhu¹, Hai-Ying Zou¹, Wang-Kai Fang¹, Yi-Yao Cui³* and Jian-Jun Xie¹*

¹Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, China, ²Department of Pathology, Medical College of Jiaying University, Meizhou, China, ³Department of Thoracic Surgery, Beijing Friendship Hospital, Affiliated to the Capital University of Medical Sciences, Beijing, China

Esophageal squamous cell carcinoma (ESCC) is a common malignant gastrointestinal tumor threatening global human health. For patients diagnosed with ESCC, determining the prognosis is a huge challenge. Due to their important role in tumor progression, long non-coding RNAs (IncRNAs) may be putative molecular candidates in the survival prediction of ESCC patients. Here, we obtained three datasets of ESCC IncRNA expression profiles (GSE53624, GSE53622, and GSE53625) from the Gene Expression Omnibus (GEO) database. The method of statistics and machine learning including survival analysis and LASSO regression analysis were applied. We identified a six-IncRNA signature composed of AL445524.1, AC109439.2, LINC01273, AC015922.3, LINC00547, and PSPC1-AS2. Kaplan–Meier and Cox analyses were conducted, and the prognostic ability and predictive independence of the IncRNA signature were found in three ESCC datasets. In the entire set, time-dependent ROC curve analysis showed that the prediction accuracy of the IncRNA signature was remarkably greater than that of TNM stage. ROC and stratified analysis indicated that the combination of six-IncRNA signature with the TNM stage has the highest accuracy in subgrouping ESCC patients. Furthermore, experiments subsequently confirmed that one of the IncRNAs LINC01273 may play an oncogenic role in ESCC. This study suggested the six-IncRNA signature could be a valuable survival predictor for patients with ESCC and have potential to be an auxiliary biomarker of TNM stage to subdivide ESCC patients more accurately, which has important clinical significance.

Keywords: esophageal squamous cell carcinoma, long non-coding RNAs, prognosis, machine learning, LASSO, LINC01273

Abbreviations: AUC, area under the ROC curve; ESCC, esophageal squamous cell carcinoma; KM, Kaplan–Meier; OS, overall survival; ROC, receiver-operating characteristic.
INTRODUCTION

Esophageal squamous cell carcinoma (ESCC) has always been a malignant gastrointestinal cancer tumor threatening human health worldwide, with high incidence and death rates (Torre et al., 2015; Chen et al., 2016). Despite the continuous development of therapeutic strategies including surgery, chemotherapy, and radiotherapy, the five-year survival rate of ESCC patients is still limited by 30–40% (Ferlay et al., 2015). A large amount of evidence indicated that tumor heterogeneity is one of the reasons for the poor clinical outcome of ESCC patients (Lin and Lin, 2019); therefore, patients exhibit distinct molecular profiles. Therefore, identification of molecular biomarkers is pivotal to predict the ESCC patients’ survival.

In recent decades, with the rapid development of computing platform of human transcriptome, microarray, and high-throughput sequencing technology, a large amount of omics data has been generated and stored in GEO and other large public databases, which will help us further reveal the molecular mechanism of tumorigenesis and explore tumor markers from the RNA level. Long non-coding RNA (lncRNA) is a type of RNA whose transcription length is >200 nucleotides and lacks the ability to encode proteins (Huarte, 2015). Accumulating evidence supports that lncRNAs can regulate both normal development and disease progression in various species (Mercer et al., 2009; Ulitsky and Bartel, 2013; Peng et al., 2017; Guo et al., 2019). Among them, a large number of lncRNAs have been regarded as critical molecules in promoting tumor growth and metastasis (Bhan et al., 2017), such as H19 (Ghafouri-Fard et al., 2020), MALAT1 (Hirata et al., 2015), PCAT-1 (Prensner et al., 2011), PCGEM1 (Srikantan et al., 2000; Shuo Chen et al., 2018), and HOTAIR (Gupta et al., 2010). In ESCC, lncRNAs, such as ZFAS1 (Li et al., 2019), CASC9 (Liang et al., 2018), GHE1 (Liu et al., 2017), TUSC7 (Chang et al., 2018), and FAM201A (Mingqiu Chen et al., 2018), have been suggested to involve in regulating ESCC epithelial–mesenchymal transition (EMT), metastasis, chemosensitivity, and radiosensitivity. Moreover, due to their high tissue- and cell-specific expression pattern, and their stability and detectability in body fluids, plasma, and urine, lncRNAs open up a new field for their applications as non-invasively diagnostic or prognostic biomarkers and therapeutic targets. A study by Feng et al. (2019) summarizes the observed lncRNAs which could be used as prognostic biomarkers of ESCC, such as SEMA3B-AS1, SNHG6, BANCR, UCA1 and MALAT1, FOXD2-AS1.

Gene expression profiling identifies many gene expression signatures from a variety of tumors, thereby enhancing our understanding of molecular alterations in the carcinogenic process and providing biomarkers for diagnosis or prognosis (Yang et al., 2020). In this research, we aim to find a prognostic biomarker for ESCC patients from the perspective of the lncRNA expression signature. Firstly, we downloaded both the lncRNA expression profiles and the matching clinical follow-up features from the GEO database. Then, Kaplan–Meier (KM) and Cox analyses were used to screen out the lncRNAs correlated with ESCC survival. Integrated bioinformatics methods were performed to establish a prognostic lncRNA signature and validate its prediction performance in multiple datasets. Finally, we confirmed that one of the lncRNAs LINC01273 may serve as an oncogene in ESCC.

MATERIALS AND METHODS

Collection of ESCC RNA Expression Profiles

The ESCC RNA expression profiles and corresponding clinical information were obtained from the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) database including GSE53624 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53624), GSE53622 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53622), and GSE53625 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53625) datasets. Samples with complete survival information are retained, while those patients without survival information are eliminated. To develop prognostic prediction lncRNA models, ESCC samples from GSE53624 were treated as a training set. GSE53622 and GSE53625 sets were test and validation datasets. The aforementioned datasets were generated with Agilent-038314 (GPL18109). Through re-annotating microarray probes (see details in the Supplementary Material) (Harrow et al., 2012; White et al., 2014; Guo et al., 2018), we gained the expression values of lncRNAs from ESCC cohorts (Supplementary Table S1). Probes with missing expression values in more than 20% of patients were discarded.

Construction of the Multi-lncRNA Predictive Models Related to Overall Survival

To single out those lncRNAs which were significantly associated with the prognosis of ESCC patients, both univariable Cox regression and KM survival analysis (the median lncRNA expression value as the cutoff value) were used in the training dataset. Those with Cox \( p < 0.05 \) and log rank \( p < 0.05 \) were considered OS-associated candidates. The LASSO regression method was then applied to obtain the strongest survival-related lncRNAs in the training set. Subsequently, the selected prognostic lncRNAs by KM, Cox, and LASSO regression were performed to develop combination models for estimating the ESCC prognosis risk as follows: risk score (RS) = \( \sum N_i = \exp(\exp * \text{coefficient}) \), where \( N \) is the number of selected lncRNAs, \( \exp \) is the corresponding lncRNAs’ expression level, and the coefficient is calculated by the univariable Cox analysis. Based on the above formula, the RS of each combination model for each ESCC patient was calculated and ROC curve analysis was applied to make comparison of the survival prediction ability among those constructed multi-lncRNA signatures in the training set.

Cell Culture and Cell Transfection

Human ESCC cell lines KYSE410 and TE5 were cultured in RPMI 1640 (Gibco) medium with 10% fetal bovine serum (TransSerum)
and 1% streptomycin–penicillin solution (Gibco). All cells were cultured in a 5% CO₂ constant temperature incubator. Small interfering RNAs (siRNAs) targeting LINC01273 (siLINC01273-1: 5'-GACACAGAAGGACAAUUGUUTT-3'; siLINC01273-2: 5'-GACAAAGUGACAGAAUGTT-3') were synthesized by Genepharma Co. (Suzhou, China). Following the instructions, siLINC01273 was transfected at a concentration of 40 nM using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) with Opti-MEM (Gibco). After transfection for 48 h, the RNAs were harvested.

**RNA Extraction and RT-qPCR**

Total RNA was reverse transcribed into cDNA by HiScript Q RT SuperMix for qPCR (Vazyme) after extracting by RNA-easy Isolation Reagent (Vazyme). The real-time RT-qPCR assay was conducted with an ABI 7500 system (Corbett Life Science) using ChamQ SYBR Color qPCR Master Mix (Vazyme) with the guide of its manufacturer's instructions. The primers for RT-qPCR of LINC01273 were 5'-TGTTTGCGGTTGCTACGGGTTTT-3' (forward) and 5'-GTCTGGCTTCTTAGTGGCC-3' (reverse). The primers for beta-actin were 5'-CAACTGGGACGACATGGAGAAA-3' (forward) and 5'-GATAGCAACGTACATGGGCTGGG-3' (reverse). The relative mRNA expression was normalized to beta-actin as reference.

**Cell Proliferation Assays**

For the MTS assay, after transfection for 36 h, 5,000 cells/well were seeded into 96-well plates. After adding MTS solution (Promega) and incubating for 2 h, the absorbance was recorded at 490 nm using an ELISA plate reader. For the colony formation assay, 500 cells/well were planted in 12-well plates and continuously grown for 2 weeks until a single colony was formed. After fixing with methanol, these colonies were stained with 0.1% crystal violet.

**Transwell**

ESCC cells were transfected with siRNAs for 36 h, and then serum starvation was performed for 12 h. For invasion assays, upper transwell chambers (Falcon) should be pre-coated with Matrigel (BD Biosciences) and then left in the incubator for 1 h. 5×10⁵ cells in 200 μL serum-free cell suspensions were added in the upper transwell chambers, while 500 μL medium containing 10% FBS was added in the bottom chamber. 36 h later, pictures were taken with a microscope magnifying ×200 after fixing and then staining the migrated or invasive cells from upper chambers.

**Statistical and Bioinformatics Analysis**

The 50th percentile of the risk score is defined as the threshold to classify the high-risk group and the low-risk group. KM analysis was applied to evaluate and validate the survival prediction performance of the lncRNA signature in different ESCC cohorts. The time-dependent ROC curve was used to compare the prediction ability of the lncRNA signature with that of other clinical features at different survival times. And univariable and multivariable Cox regression and stratification analysis were used to test whether the multi-lncRNA risk score model was independent of other clinical characters. The R program (3.5.1) including R packages named survival, survminer, glmnet, pROC, and timeROC was used to perform the above analyses.

To explore the potential biological functions of lncRNAs, the Pearson correlation test was used to construct co-expressed networks of lncRNAs and the protein-coding genes (PCGs) in the GSE53625 dataset, and the PCGs that were highly correlated with lncRNAs (correlation coefficient >0.60/≤-0.6, p < 0.001) were selected for GO and KEGG pathway enrichment analysis by the Cluego plugin in Cytoscape (Guo et al., 2018). SubpathwayMiner was also used to identify related pathways of the co-expressed PCGs in the KEGG database including entire pathways and sub-pathways.

All experiments were repeated for at least three times. The values are shown as mean ± SD. Prism 8 software was used to perform statistical analyses. Student’s t-test was employed for comparisons between two groups, and one-way ANOVA was performed for multiple-group comparisons. The differences with *p < 0.05, **p < 0.01, ***p < 0.001 were considered statistically significant.

**RESULTS**

**ESCC Clinical Characteristics and Expression Profiles**

There were a total of 179 ESCC samples used in this study, including 119 from GSE53624 and 60 from GSE53622.
respectively. GSE53625 is the union of GSE53624 and GSE53622. The median survival age was 60 years. There were more male patients with ESCC than females (146 vs 33), and most of the patients were dead (survival time, 3 days to 60 months). Other clinical characters are shown in Table 1. In addition, through re-annotating microarray probes, a total of 6,253 expressed lncRNAs and 17,434 expressed PCGs were obtained from GSE53624 and GSE53622. Identification of the Prognostic lncRNAs in the Training Set ESCC samples from GSE53624 (n = 119) were treated as the training dataset to evaluate the relationship between ESCC OS and lncRNAs. After univariate Cox and KM analysis of lncRNAs’ expression level with clinical survival information, we identified a total of 209 lncRNAs (Figure 1A) related to ESCC patients’ OS significantly (Cox p < 0.05 and log rank p < 0.05), which could be used as prognostic candidates. Then, the LASSO regression algorithm via regression coefficient shrinkage based on a penalty that is proportional to size was utilized to screen out lncRNAs which were mostly correlated with ESCC survival among the 209-lncRNA set. As shown in Figure 1B, we found that the value of independent coefficients tended to zero with the increase of lambda value. Finally, we used threefold cross-validation and selected seven lncRNA candidates to construct the multi-lncRNA classifiers (Figure 1C).

Construction of the Six-lncRNA Prognostic Signature To select a better predictive multi-lncRNA model with fewer lncRNAs, ROC curve analysis was performed to compare the prognostic prediction performance of the $2^7-1 = 127$ risk score combinations in the training dataset (Supplementary Table S2). All risk scores for each ESCC based on the corresponding lncRNA signature were calculated as the method described. Then, the six-lncRNA combination with the largest AUC value composed by AL445524.1, AC109439.2, LINC01273, AC015922.3, LINC00547, and PSPC1-AS2 was obtained (Figure 1D; Table 2). The RS of the six-lncRNA signature is as follows: $RS = (-0.5460037 \times AL445524.1) + (-0.2473264 \times AC109439.2) + (0.4223392 \times LINC01273) + (-0.81843 \times AC015922.3) + (0.7987309 \times LINC00547) + (0.8210199 \times PSPC1-AS2)$. The AUC of the six-lncRNA signature was 0.863 (95% CI: 0.798 – 0.928), higher than that of the seven-lncRNA model (0.855, 95% CI: 0.787 – 0.924, Figures 1E,F) and other lncRNA combinations. Therefore, we chose the six-lncRNA signature with fewer nodes and better survival prediction ability as the candidate classifier.

Evaluation and Validation of the Prognostic lncRNA Model in ESCC In the GSE53624 set, on the basis of the median risk score calculated by the six-lncRNA signature, patients were distinguished into two groups with different OS.

![FIGURE 1](https://example.com/figure1.png)
Unfortunately, patients with ESCC from the high-risk group suffered a worst survival outcome than those from the low-risk group (log rank \( p < 0.001 \), Figure 2A). The five-year survival rate of patients in the low-risk group was 63.3%, which was significantly more than 15.25% of patients in the high-risk group.

**TABLE 2** | Prognostic significance of the six lncRNAs in the signature.

| Ensembl ID       | Gene name   | HR  | 95% CI of HR         | \( p \) | Chromosome location |
|------------------|-------------|-----|----------------------|--------|--------------------|
|                  |             |     | Lower                | Upper  |
| ENSG00000233461  | AL445524.1  | 0.579 | 0.432                | 0.778  | <0.001             |
| ENSG00000250284  | AC109439.2  | 0.781 | 0.664                | 0.918  | 0.003              |
| ENSG00000231742  | LINC01273   | 1.526 | 1.148                | 2.026  | 0.004              |
| ENSG00000276855  | AC015922.3  | 2.209 | 1.403                | 3.477  | 0.001              |
| ENSG00000275226  | LINC00547   | 2.223 | 1.523                | 3.243  | <0.001             |
| ENSG00000226352  | PSPC1-AS2   | 2.273 | 1.587                | 3.256  | <0.001             |

**FIGURE 2** | Kaplan–Meier analysis of the six-lncRNA signature in the GSE53624 (A), GSE53622 (B), and GSE53625 (C) datasets.

**FIGURE 3** | Expression heatmap of the six lncRNAs, plot of six-lncRNA risk scores, and ESCC patient’s survival status in the GSE53624 (A), GSE53622 (B), and GSE53625 (C) datasets.
The high-risk group was 39.17 months less than 50.6 months in GSE53622 dataset. We found that the median survival time in GSE53622, GSE53624, and GSE53625 datasets (III vs. I + II: HR = 1.8, p < 0.001, n = 119; HR = 2.37, p = 0.009, n = 60; HR = 1.95, p < 0.001, n = 179, Table 3).

Comparison of the Six-IncRNA Signature With Clinical Features in Survival Prediction Ability
Time-dependent ROC curve analysis from 1 year to 5 years was applied to compare the survival prediction ability of the IncRNA signature with that of tumor grade, TNM stage, T stage, and N stage in the entire ESCC group (GSE53625, n = 179). The AUC values showed the predictive ability of the IncRNA signature (AUC from 1 year to 5 years: 0.698–0.909) was better than that of TNM stage (AUC from 1 year to 5 years: 0.486–0.67) and other features, especially at 5 years (Figure 4A). And the AUC of the combined model was the largest one compared to that of TNM stage or signature alone (AUC = 0.712, 95% CI = 0.645–0.779, Figure 4B), which further suggested the signature has potential to become a novel prognostic biomarker.

Stratification Analysis of the Six-IncRNA Signature
To evaluate whether the signature can further subgroup ESCC patients at high (III)/low (I, II) TNM stage, we performed stratification analysis in the entire dataset (GSE53625, n = 179). According to the TNM stage information of all the 179 patients, we found 87 patients at TNM low stage and 92 at TNM high stage. For patients at low TNM stage, the six-IncRNA signature could separate them into low- and high-risk groups with significantly different survival (five-year survival rate 59.1% vs. 18.6%, log rank test p < 0.001, Figure 4C). The signature can further classify patients at the high TNM stage into two groups with different prognostic outcomes (median survival: 28.7 months vs. 58.2 months; log rank test p < 0.001, Figure 4D). This result showed the potential ability of the six-

### TABLE 3 | Cox regression analysis of the signature with ESCC survival.

| Variables       | GSE53624 Univariable analysis | GSE53625 Univariable analysis |
|-----------------|-------------------------------|-------------------------------|
|                 |     | HR (95% CI of HR) p          |     | HR (95% CI of HR) p          |
|                 | Lower | Upper |     | Lower | Upper |
| Age >60 vs. ≤60 | 1.42 | 0.90 | 2.25 | 0.14 | 1.66 | 1.02 | 2.72 | 0.04 |
| Sex Male vs. female | 0.83 | 0.47 | 1.46 | 0.51 | 1.29 | 0.70 | 2.38 | 0.42 |
| TNM stage III vs. II, I | 1.90 | 1.23 | 2.95 | <0.001 | 1.80 | 1.15 | 2.83 | 0.01 |
| Signature High risk vs. low risk | 4.50 | 2.71 | 7.46 | <0.001 | 4.97 | 2.94 | 8.42 | <0.001 |

| Variables       | GSE53624 Multivariable analysis | GSE53625 Multivariable analysis |
|-----------------|-------------------------------|-------------------------------|
|                 |     | HR (95% CI of HR) p          |     | HR (95% CI of HR) p          |
|                 | Lower | Upper |     | Lower | Upper |
| Age >60 vs. ≤60 | 2.07 | 1.02 | 4.21 | 0.05 | 1.79 | 0.87 | 3.71 | 0.12 |
| Sex Male vs. female | 0.71 | 0.31 | 1.64 | 0.42 | 0.54 | 0.22 | 1.34 | 0.18 |
| TNM stage III vs. II, I | 2.12 | 1.15 | 3.91 | 0.02 | 2.37 | 1.24 | 4.53 | 0.01 |
| Signature High risk vs. low risk | 2.26 | 1.11 | 4.61 | 0.02 | 2.26 | 1.11 | 4.60 | 0.03 |

For verifying the survival classification power of the IncRNA model, each patient from the validation GSE53622 set obtained their risk score values. Figure 2B shows the KM curves for patients with ESCC from the low/high-risk group in the GSE53622 dataset. We found that the median survival time in the high-risk group was 39.17 months less than 50.6 months in the low-risk group (five-year survival rate: 30% vs. 60%, log rank test p = 0.021). As for the entire dataset (GSE53625), patients with high risk scores suffered more undesirable outcomes than those with low risk scores (median survival time: 23.13 months vs. 51.3 months; log rank test p < 0.001, Figure 2C).

Moreover, Figure 3 shows the IncRNAs’ expression pattern of ESCC patients, the distribution of survival status, and their risk scores. For ESCC patients with high risk scores from the training set, the expression values of four lncRNAs (LINC01273, AC015922.3, LINC00547, PSPC1-AS2) were high, while the expression values of protective lncRNAs (AL445524.1, AC109439.2) were low. In contrast, the expression of prognostic lncRNAs showed the opposite pattern in patients with low risk scores in the training set (Figure 3A). Subsequently, we confirmed the similar survival distribution and risky or protective lncRNAs’ expression pattern in GSE53622 and GSE53625 sets (Figures 3B,C).

### Evaluation of Survival Prediction Independence
To evaluate the independence of the signature in survival prediction with other clinical characters including age, gender, and TNM stage, Cox regression analysis in GSE53624, GSE53622, and GSE53625 datasets was performed, and the multivariate Cox results of the multiple ESCC datasets showed that the six-IncRNA signature in OS prediction was independent of age and gender (high vs. low risk, HR = 4.97, p < 0.001, n = 119; HR = 2.26, p = 0.025, n = 60; HR = 2.11, p < 0.001, n = 179, Table 3).

Additional information can be found in Table 3, which provides a detailed comparison of the six-IncRNA signature with clinical features in survival prediction ability.
IncrRNA signature as a clinical auxiliary marker for TNM stage to subgroup patients with ESCC more accurately.

**Functional Prediction of IncRNAs From the Six-IncrRNA Signature**

The Pearson test observed that the expression of 491 PCGs was significantly related to at least one of the six prognostic IncRNAs (coefficient >0.60/−0.60, p < 0.001). GO and KEGG function analysis was then performed by Cluego and SubpathwayMiner. The results showed the 491 PCGs correlated with IncRNAs were significantly enriched in 37 GO terms and 36 KEGG pathways (p < 0.05, Supplementary Table S3). All these vital GO terms were organized into an interaction network based on similar functions in Cytoscape, and several clusters of functionally related GO terms were found such as ncRNA metabolic process, RNA process via interacting with those PCGs that affect cell cycle, regulation of actin cytoskeleton, MAPK signaling pathway, cell cycle, and TGF-β signaling pathway (Supplementary Figure S1B).

**Oncogenic Effect of LINC01273 in ESCC Cells**

We next investigated the biological roles of LINC01273 in maintaining the malignant phenotypes of ESCC cells. LINC01273 expression was examined in ESCC cell lines which our lab owned using qRT-PCR, and the results showed that LINC01273 was highly expressed in KYSE410 and TE5 cells (Figure 5A). Therefore, KYSE410 and TE5 cell lines were selected for further experiments. Firstly, we, respectively, transfected two individual siRNAs and confirmed LINC01273 was successfully knocked down by qRT-PCR (Figure 5B). We found that, by using the MTT assay and cell colony formation assay, silencing LINC01273 remarkably attenuated both the proliferation and colony formation capability of ESCC cells (Figures 5C,D). Transwell assays showed a significant suppression of the migration and invasive abilities of the two ESCC cell lines due to LINC01273 downregulation (Figures 5E,F). These results suggested that LINC01273 might enhance the ability of proliferation, migration, and invasion of KYSE410 and TE5 cells, demonstrating that LINC01273 may play oncogenic roles in ESCC.

**DISCUSSION**

Esophageal cancer ranks eighth in the global incidence of malignant tumors and sixth in tumor-related mortality. ESCC, the most common subtype of esophageal cancer, is so extremely aggressive that recent medical developments have not improved the prognosis of patients. TNM stage is still the main tool for predicting the survival of ESCC (Kang et al., 2020). However, ESCC patients with
FIGURE 5 | Oncogenic effect of LINC01273 on ESCC cells. (A) RT-qPCR analysis of LINC01273 expression in ESCC cell lines. (B) siRNA-mediated silencing of LINC01273 was evaluated by using RT-qPCR. (C,D) Results of the MTS assay (C) and colony formation assay (D) demonstrated that cell proliferation was inhibited after depletion of LINC01273 in KYSE410 and TE5 cells. (E,F) Transwell assays suggested that migration (E) and invasion (F) abilities were reduced after LINC01273 knockdown. All data are expressed as mean ± SD (*p < 0.05, **p < 0.01, ***p < 0.001).
the same pathological characteristics at diagnosis often have completely different survival outcomes (Matsueda and Ishihara, 2020). For ESCC patients, the application of molecular characteristics to prognostic prediction may help resolve tumor heterogeneity and achieve precise treatment and evaluation. Accumulating evidence shows that lncRNAs are functional regulatory molecules in a variety of tumors. In ESCC, it is reported that lncRNAs regulate tumor progression through multiple mechanisms and multiple molecular interactions (Feng et al., 2019) and have the prognostic value because they are too closely related to survival (Deng et al., 2016). Therefore, exploring a prognostic lncRNA signature from ESCC patients would be meaningful and urgently necessary.

In this study, we achieved and re-mined the publicly available lncRNA profiles of ESCC (Li et al., 2014) and identified a total of 209 survival-related IncRNAs by KM and Cox survival analysis. Then, we developed a six-lncRNA model including AL445524.1, AC109439.2, LINC01273, AC015922.3, LINC00547, and PSPC1-AS2, which was significantly correlated with the prognosis of ESCC. Different from most of the existing prognostic model construction process (Zeng et al., 2018; Bao et al., 2019; Liu et al., 2019; Wang et al., 2019), following LASSO regression analysis which reduced the number of prognostic IncRNAs directly from 209 to 7, we added a key step, permutation and combination of the LASSO-selected IncRNAs, which further diminished the node number in the signature and greatly improved the clinical utility of the signature. Consistent with the risk model construction and prognostic signature screening methods reported in other literature (Guo et al., 2016), we further performed ROC curve analysis on RS models and screened the signature with the strongest predictive ability from multiple signatures composed of seven IncRNAs. In addition, because the AUC value of our six-lncRNA signature is greater than that of other signatures discovered by some researchers (Zhang et al., 2020), our signature performs better in prognostic prediction.

Moreover, we accessed the independence of the six-lncRNA signature from other ESCC clinical characteristics including age, sex, and TNM stage by Cox regression analysis in multiple ESCC datasets and showed it was an independent prognostic factor. ROC curve analysis results suggested the lncRNA signature had better accuracy in survival prediction than TNM stage, and the combination of TNM stage and lncRNA signature can evaluate the prognosis of patients more accurately. Stratified analysis indicated the ESCC patients at high/low TNM stages could be further separated into two different groups with significantly different survival. Taken together, the six-lncRNA signature could be a valuable classifier for ESCC prognosis and have potential to become an auxiliary biomarker for TNM stage to subdivide patients effectively.

As for the prognostic correlation of six prognostic IncRNAs, the high expression of four risk IncRNAs, LINC01273, AC015922.3, LINC00547, and PSPC1-AS2, was related to poor survival (Cox coefficient >0, p < 0.01), and the remaining protective IncRNAs (AL445524.1 and AC109439.2) were associated with longer survival time (Cox coefficient <0, p < 0.01). The biological functions of these six IncRNAs in cancer have not been reported until now. However, we have demonstrated that one of the IncRNAs of the six-lncRNA signature, LINC01273, may act as an oncogenic lncRNA to improve the abilities of proliferation, migration, and invasion in ESCC, which suggested the importance of LINC01273 in the six-lncRNA signature and other five IncRNAs may play key roles in ESCC as well. Moreover, our functional enrichment analysis results revealed that they may participate in tumorigenesis by cell cycles, MAPK signaling pathway, and TGF-beta signaling pathway. Accumulating studies suggested that the TGF-beta signaling pathway plays an important role in many kinds of cancers due to its importance in migration and EMT which is closely related to chemotherapy resistance (Colak and Ten Dijke, 2017).

So far, we have only demonstrated that LINC01273 may function as an oncogenic IncRNA. Although the potential function of these IncRNAs has been predicted by bioinformatics methods principally, the roles of these IncRNAs in ESCC are still unclear and need more experimental studies to further elucidate in the future. Another drawback of this study is that the model has not been tested and verified in clinical trials. Despite these shortcomings, the significant and consistent correlation between the lncRNA signature and OS in multiple ESCC datasets indicated that the six-lncRNA signature is a powerful prognostic marker of ESCC. Furthermore, our current experiment has confirmed the carcinogenic effect of LINC01273 on ESCC.

In conclusion, the six-lncRNA signature constructed in this study could predict the survival of ESCC patients more accurately and have the potential to be an auxiliary molecular biomarker of TNM stage in prognosis.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. These data can be found here: ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE53nnn/GSE53624/matrix/ ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE53nnn/GSE53622/matrix/ ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE53nnn/GSE53625/matrix/.

AUTHOR CONTRIBUTIONS

Z-JZ was the major contributor in writing the manuscript and investigation and performed the integrated bioinformatics methods to analyze and interpret the data. Y-SL made contributions to conception and design. J-DZ participated in drawing figures and statistical analysis. H-YZ and W-KF were involved in revising and editing the paper. J-JX and Y-YC provided overall direction. All authors read and approved the final manuscript.

FUNDING

This work was supported by grants from the National Natural Science Foundation of China (81871921, 81773138), the Natural Science Foundation of Guangdong Province-Outstanding Youth Project (2019B151502059), the Basic and Applied Basic Research Programs of Guangdong Province (Nos. 2018KZDXM033,
REFERENCES

A Novel Epigenetic Signature for Overall Survival Prediction in Patients with Breast Cancer. J. Transl. Med. 17, 380. doi:10.1186/s12967-019-2126-6

Long Non-coding RNA and Cancer: A New Paradigm. Cancer Res. 77, 3965–3981. doi:10.1158/0008-5472.can-16-2634

Affected Chemotherapy Resistance of Esophageal Squamous Cell Carcinoma by Competitively Regulating DISC1. J. Exp. Clin. Cancer Res. 37, 56. doi:10.1186/s13046-018-0724-4

Chen, S., Wang, L.-l., Sun, K.-x., Liu, Y., Guan, X., Zong, Z.-h., et al. (2018). Long Non-coding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through EZH2 and Interacts with miR-205. Cancer Res. 75, 1322–1331. doi:10.1158/0008-5472.can-14-2931

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.839589/full#supplementary-material

Supplementary Figure S1 | Functional enrichment analysis of the six IncRNAs by Ouego (A) and SubpathwayMiner (B).

Supplementary Table S1 | Re-annotating probes for Agilent-038314 MB Homo sapiens IncRNA + mRNA microarray V2.0.

Supplementary Table S2 | 127 signatures comprising different IncRNAs in the GSE53624 dataset (n =119).

Supplementary Table S3 | Functional enrichment analysis of the six IncRNAs by Ouego and SubpathwayMiner.
Wang, L., Shi, J., Huang, Y., Liu, S., Zhang, J., Ding, H., et al. (2019). A Six-Gene Prognostic Model Predicts Overall Survival in Bladder Cancer Patients. *Cancer Cell Int.* 19, 229. doi:10.1186/s12935-019-0950-7

White, N. M., Cabanski, C. R., Silva-Fisher, J. M., Dang, H. X., Govindan, R., and Maher, C. A. (2014). Transcriptome Sequencing Reveals Altered Long Intergenic Non-coding RNAs in Lung Cancer. *Genome Biol.* 15, 429. doi:10.1186/s13059-014-0429-8

Yang, H., Su, H., Hu, N., Wang, C., Wang, L., Giffen, C., et al. (2020). Integrated Analysis of Genome-wide miRNAs and Targeted Gene Expression in Esophageal Squamous Cell Carcinoma (ESCC) and Relation to Prognosis. *BMC Cancer* 20, 388. doi:10.1186/s12885-020-06901-6

Zeng, D., Zhou, R., Yu, Y., Luo, Y., Zhang, J., Sun, H., et al. (2018). Gene Expression Profiles for a Prognostic Immunoscore in Gastric Cancer. *Br. J. Surg.* 105, 1338–1348. doi:10.1002/bjs.10871

Zhang, L., Li, P., Liu, E., Xing, C., Zhu, D., Zhang, J., et al. (2020). Prognostic Value of a Five-lncRNA Signature in Esophageal Squamous Cell Carcinoma. *Cancer Cell Int.* 20, 386. doi:10.1186/s12935-020-01480-9

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zheng, Li, Zhu, Zou, Fang, Cui and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.